Myriad Genetics Reports Fiscal Fourth-Quarter 2017 and Fiscal Full-Year 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Tesla acquires AI hardware company for up to $2 billion in stock
Myriad Genetics (MYGN) PT Raised to $23 at Jefferies
August 9, 2017 8:40 AM EDTJefferies raised its price target on Myriad Genetics (NASDAQ: MYGN) to $23.00 (from $21.00) while maintaining a Hold rating. MYGN's initial FY18 revenue outlook fell ~$30M below consensus, owing to ASP headwinds it will absorb in hereditary cancer from steps taken to secure LT, fixed-price... More
Myriad Genetics (MYGN) Tops Q4 EPS by 4c
August 8, 2017 4:23 PM EDTMyriad Genetics (NASDAQ: MYGN) reported Q4 EPS of $0.30, $0.04 better than the analyst estimate of $0.26. Revenue for the quarter came in at $200.5 million versus the consensus estimate of $193.74 million.
GUIDANCE:
Myriad Genetics sees FY2018 EPS of $1.00-$1.05. Myriad Genetics sees FY2018... More
